“Ferring Pharmaceuticals Inc., Ferring International Center S.A., Ferring B.V., and Polypeptide Laboratories A/S (collectively, “Ferring”) and Defendants Eugia Pharma Specialties, Ltd., Aurobindo Pharma Ltd., and Eugia US LLC f/k/a Auromedics Pharma LLC (collectively, “Eugia”), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of the action and have set forth those terms and conditions in a Settlement Agreement (the “Settlement Agreement”). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the action, as follows: IT IS this 7th day of June 2024: ORDERED, ADJUDGED AND DECREED as follows: 1. This District Court has jurisdiction over the subject matter of the above actions and has personal jurisdiction over the parties. 2. As used in this Consent Judgment, (i) the term “Eugia Product(s)” shall mean Degarelix for Injection, 80 mg/vial and 120 mg/vial, products that are described in Eugia’s Abbreviated New Drug Application No. 215800, including amendments and/or supplements thereto (and defined in greater detail in the Settlement Agreement); (ii) the term “Licensed Patents” shall have the meaning according to the definitions in the Settlement Agreement; and (iii) the term “Affiliate” shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Eugia; for purposes of this definition, “control” means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. 3. Eugia, for itself and its Affiliates, including respective predecessors, successors, assigns, agents, officers, employees, and representatives, have acknowledged, admitted, and agreed that the asserted claims of the Patents-in-Suit are valid and enforceable solely with respect to the making, having made, use, sale, offer to sell, or importation of the Eugia Product(s). 4. Eugia, for itself and its Affiliates, including respective predecessors, successors, assigns, agents, officers, employees, and representatives, have acknowledged, admitted, and agreed that, absent a valid license to the Patents-in-suit, the Patents-in-suit would be infringed by the making, having made, use, sale, offer to sale, or importation of Eugia’s Product(s) in or for the United States. 5. Unless otherwise specifically authorized pursuant to the Settlement Agreement, Eugia, including any of its Affiliates, successors, and assigns, is enjoined from infringing the Licensed Patents, on its own part or through any Affiliate, by making, having made, using, selling, offering to sell, importing or distributing of the Eugia Product. 6. Compliance with this Consent Judgment may be enforced by Ferring and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement. 7. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement. 8. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys’ fees to any party.”